NSABP B-42: A clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer

Eleftherios P. Mamounas, Barry Lembersky, Jong Hyeon Jeong, Walter Cronin, Barbara Harkins, Charles Geyer, Donald Lawrence Wickerham, Soonmyung Paik, Joseph Costantino, Norman Wolmark

Internal Medicine

Research output: Contribution to journal › Article › peer-review

40 Scopus citations

Fingerprint

Dive into the research topics of 'NSABP B-42: A clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer'. Together they form a unique fingerprint.